Embody vs Hers
An in-depth comparison of two leading GLP-1 Providers
Some of the links on this page earn us money. If you sign up with a provider after following one, that provider may pay GLP Watchdog a commission. Learn more
Embody
Best for: knowing which pharmacy fills the vial — it names RedRock Pharmacy
Visit Embody →
Hers
Best for: coverage in all 50 states, which most of the register will not confirm
Visit Hers →Two GLP-1 Providers chasing the same patients, trading off price, geography and what lands in the box differently. On our scoring, Embody opens cheaper — $79/mo against $199, and Embody finishes ahead, 9.3 to 6.6. What follows: the prices, what each plan actually covers, the six-dimension score, where each one is weak, and who should pick which.
Pricing
Embody
Checkout: '$79/mo flat forever' (strikethrough $299); bundles $76/$73/$69 per month on 3/6/12-mo. CAVEAT: T&C list price is $199/mo — the $79 depends on the auto-applied SUMMER promo marketed as permanently locked; Trustpilot complaints allege the lock was not always honored.
Checkout tile 'Flat rate at $119/month (strikethrough $349)'; homepage 'starting at $129/month'; bundles $126/$123/$119 per month.
New oral semaglutide $229/mo.
Oral tirzepatide $329/mo; gum bundles to $299/mo at 12-month.
Hers
Brand Zepbound from $299/mo medication-only; requires Hers Weight Loss Membership ($149/mo)
What’s included
Embody
Covered by the monthly price
Medication
In the price
Clinician visits
In the price
Shipping
In the price
Lab work
Not stated
Coaching
Not stated
Hers
Covered by the monthly price
Medication
In the price
Clinician visits
Charged on top
Shipping
Not stated
Lab work
Not stated
Coaching
Charged on top
Score breakdown
Both providers are scored on the same six-dimension framework. The gradient bar marks the stronger side on each dimension.
Embody
9.3/10
Hers
6.6/10
Value25%
Effectiveness25%
User Experience15%
Trust & Safety15%
Accessibility10%
Support10%
Features & Coverage
| Feature | Embody | Hers |
|---|---|---|
| Starting Price | ✓$79/mo | $199/mo |
| Features | ✓6 features | 2 features |
| States Available | 50 | 50 |
| Compounded | ✓ Yes | ✓ Yes |
| Brand Name | — | ✓ Yes |
| FSA/HSA Accepted | — | — |
| FDA Warnings | ✓None | 1 warning |
About Embody
Embody sells compounded semaglutide and tirzepatide by injection, plus a compounded oral tirzepatide gum that is unique in the category. Flat-rate pricing is aggressive, coverage runs to all 50 states, and clinician messaging is available 24/7 under a board-certified internal medicine CMO.
Read our full Embody review →About Hers
Hers is the women-focused telehealth brand from Hims and Hers. It sells compounded semaglutide on a 6-month plan.
Read our full Hers review →Pros & Cons
Embody
What we like
- Semaglutide at $79 a month, 58% below the $189 median for the same drug and form across this register
- Tirzepatide at $129 a month, 52% below the $267 median for the same drug and form across this register
- Publishes a price on its own site before the medical questionnaire, so it can be compared without handing over health information
- The monthly figure covers medication, consult, shipping
- Coverage is published for all 50 states
- Names 4 dispensing pharmacies, which most sellers in this register do not do
- No FDA warning letter matched this operator when we searched our enforcement register
- Both oral and injectable options are on record, so the format is a choice rather than a condition
Watch-outs
- Its semaglutide and tirzepatide are compounded rather than FDA-approved, so they have not been reviewed by the agency for safety, effectiveness or manufacturing quality
Hers
What we like
- Publishes a price on its own site before the medical questionnaire, so it can be compared without handing over health information
- The monthly figure covers medication
- Coverage is published for all 50 states
Watch-outs
- Billed separately from the monthly figure: consult, coaching
- No dispensing pharmacy is named in our record, so its accreditation cannot be looked up from here
- 1 FDA warning letter matched to this operator in our enforcement register — read what the letter alleges, since a letter discloses a problem rather than disqualifying a seller
- Its semaglutide is compounded rather than FDA-approved, so it has not been reviewed by the agency for safety, effectiveness or manufacturing quality
Our Verdict
Embody takes it, 9.3 against 6.6, and it is especially strong on knowing which pharmacy fills the vial — it names RedRock Pharmacy. Hers is no weak second and may fit you better on coverage in all 50 states, which most of the register will not confirm.
Choose Embody if…
You want knowing which pharmacy fills the vial — it names RedRock Pharmacy and an opening price near $79 a month.
Choose Hers if…
You want coverage in all 50 states, which most of the register will not confirm and an opening price near $199 a month.
Ready to start? Vetted GLP-1 providers
Vetted telehealth providers that prescribe GLP-1 online.
No insurance needed · vetted by our editors
Some of the links on this page earn us money. If you sign up with a provider after following one, that provider may pay GLP Watchdog a commission. Learn more
Found
Tirzepatide at $169/month, 37% under the register median
From $99/mo
Get started →Telos Rx
Starting below a standard dose, with microdose tiers
From $49/mo
Get started →MyDrHank
An oral route if you will not self-inject
From $25/mo
Get started →Embody vs Hers: FAQ
Glossary
The words sellers use, defined. Tap any term.
- Semaglutide · Drugs and brands
- Tirzepatide · Drugs and brands
- Compounded GLP-1 · Pharmacy and drug forms
- 503A pharmacy · Pharmacy and drug forms
- PCAB accreditation · Pharmacy and drug forms
- Prior authorization (PA) · Insurance and regulatory
- Off-label use · Insurance and regulatory
- FDA Drug Shortage List · Insurance and regulatory
Related comparisons
Continue exploring Embody and Hers head-to-heads in the same category.
- Embody vs Trimi Health
- Embody vs He & She MD
- Embody vs Lean Meds
- Hers vs NextMeds
- Hers vs bmiMD
- Hers vs CoreAge Rx
Or see the full category ranking.
Novo Nordisk A/S owns the Wegovy®, Ozempic® and Rybelsus® marks; Eli Lilly and Company owns Mounjaro® and Zepbound®. Every other product name and mark on this page belongs to whoever owns it. No pharmaceutical manufacturer is affiliated with GLP Watchdog. See trademark disclaimer.